Department of Pathology, University of Illinois at Chicago, Chicago, Illinois.
Data from human epidemiological studies, cultured mammalian cells, and animal models have supported a potentially beneficial role of selenium (Se) in prostate cancer prevention. In addition, Se-containing proteins including members of the glutathione peroxidase (GPx) family and Selenium-Binding Protein 1 (SBP1) have been linked to either cancer risk or development. For example, SBP1 levels are typically reduced in tumors compared to non-cancerous tissue, with the degree of reduction associated with increasingly poor clinical outcome.
In order to investigate inter-relationships between blood and tissue Se levels and GPx activity, tissue SBP1 levels, and disease aggressiveness using the Gleason score, we measured levels of selenium and selected selenoproteins in fasting serum and histologically normal prostate tissues obtained from 24 men undergoing radical prostatectomy for the treatment of localized prostate cancer.
GPx enzyme activity was inversely correlated with SBP1 levels in prostate tissue as determined by densitometry of Western blots obtained using anti-SBP1 antibodies [partial Spearman's correlation coefficients and corresponding P-values overall and in African-Americans = -0.42 (0.08) and -0.53 (0.10), respectively], which is consistent with previous observations in cultured cells and mice. Of particular interest was the positive correlation between tissue GPx activity and Gleason score, with this relationship achieving statistical significance among African-Americans (r = 0.67, P = 0.02).
These studies support the continued investigation of the role of Se and selenoproteins in prostate cancer prevention, development, and prognosis.
Written by:
Jerome-Morais A, Wright ME, Liu R, Yang W, Jackson MI, Combs GF Jr, Diamond AM. Are you the author?
Reference: Prostate. 2011 Nov 9. Epub ahead of print.
doi: 10.1002/pros.21506
PubMed Abstract
PMID: 22072582
UroToday.com Prostate Cancer Section
